Wall Street Ends Lower as AI Stocks Drag Markets, Fed Rate Outlook Shifts 
US Supreme Court Strikes Down Hawaii Gun Carry Law on Private Property 
Trump Administration Urges Judge to Allow UFC Event on White House Lawn 
Gold Drops Below $4,000 as Strong US Dollar and Fed Rate Hike Expectations Pressure Bullion 
BOJ Hawk Signals Faster Interest Rate Hikes Amid Inflation Risks 
Asian Markets Rally as Micron and Qualcomm AI Outlook Lifts Global Tech Stocks 
DOJ Sues Virginia Over Law Enforcement Mask Ban 
Trump Threatens ABC News Lawsuit Over Lincoln Memorial Reflecting Pool Coverage 
Asian Stocks Sink as Apple Price Hikes Spark AI Valuation Fears, South Korea and Japan Lead Selloff 
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
Trump Administration Defends Anthropic AI Restrictions in Ongoing Federal Lawsuit 
Trump Team Rejects BBC Financial Data Request in $10B Lawsuit 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Gold Falls Below $4,000 as Strong Dollar and Fed Rate Hike Expectations Weigh on Prices 
US Appeals Court Keeps Trump’s 10% Global Tariff in Effect During Ongoing Legal Battle 
US Dollar Slips After PCE Inflation Data as Fed Rate Hike Expectations Stay Elevated 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
